AAAAAA

   
Results: 1-25 | 26-40
Results: 1-25/40
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and leukemia group B study 8662
Authors: Hayes, DF Yamauchi, H Broadwater, G Cirrincione, CT Rodrigue, SP Berry, DA Younger, J Panasci, LL Millard, F Duggan, DB Norton, L Henderson, IC
Citation: Df. Hayes et al., Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and leukemia group B study 8662, CLIN CANC R, 7(9), 2001, pp. 2703-2711
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner -See The Biology Behind: E. A. Sausville, combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: Sequence and tumor biology matters. Clin. Cancer Res., 7: 2155-2158, 2001.
Authors: Munster, PN Basso, A Solit, D Norton, L Rosen, N
Citation: Pn. Munster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner -See The Biology Behind: E. A. Sausville, combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: Sequence and tumor biology matters. Clin. Cancer Res., 7: 2155-2158, 2001., CLIN CANC R, 7(8), 2001, pp. 2228-2236
High-dose chemotherapy for breast cancer: "How do you know?"
Authors: Norton, L
Citation: L. Norton, High-dose chemotherapy for breast cancer: "How do you know?", J CL ONCOL, 19(11), 2001, pp. 2769-2770
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
Authors: Seidman, AD Fornier, MN Esteva, FJ Tan, L Kaptain, S Bach, A Panageas, KS Arroyo, C Valero, V Currie, V Gilewski, T Theodoulou, M Moynahan, ME Moasser, M Sklarin, N Dickler, M D'Andrea, G Cristofanilli, M Rivera, E Hortobagyi, GN Norton, L Hudis, CA
Citation: Ad. Seidman et al., Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification, J CL ONCOL, 19(10), 2001, pp. 2587-2595
Oral gossypol in the treatment of patients with refractory metastatic breast cancer: A phase I/II clinical trial
Authors: Van Poznak, C Seidman, AD Reidenberg, MM Moasser, MM Sklarin, N Van Zee, K Borgen, P Gollub, M Bacotti, D Yao, TJ Bloch, R Ligueros, M Sonenberg, M Norton, L Hudis, C
Citation: C. Van Poznak et al., Oral gossypol in the treatment of patients with refractory metastatic breast cancer: A phase I/II clinical trial, BREAST CANC, 66(3), 2001, pp. 239-248
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial
Authors: Cauley, JA Norton, L Lippman, ME Eckert, S Krueger, KA Purdie, DW Farrerons, J Karasik, A Mellstrom, D Ng, KW Stepan, JJ Powles, TJ Morrow, M Costa, A Silfen, SL Walls, EL Schmitt, H Muchmore, DB Jordan, VC
Citation: Ja. Cauley et al., Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial, BREAST CANC, 65(2), 2001, pp. 125-134
Global tobacco control
Authors: Norton, L Bunn, P
Citation: L. Norton et P. Bunn, Global tobacco control, LANCET, 358(9285), 2001, pp. 924-924
Search and selection processes in implicit and explicit word-stem completion performance in young, middle-aged, and older adults
Authors: Ryan, L Ostergaard, A Norton, L Johnson, J
Citation: L. Ryan et al., Search and selection processes in implicit and explicit word-stem completion performance in young, middle-aged, and older adults, MEM COGNIT, 29(5), 2001, pp. 678-690
Use of chemotherapy plus a monoclonal antibody against HER2 for metastaticbreast cancer that overexpresses HER2.
Authors: Slamon, DJ Leyland-Jones, B Shak, S Fuchs, H Paton, V Bajamonde, A Fleming, T Eiermann, W Wolter, J Pegram, M Baselga, J Norton, L
Citation: Dj. Slamon et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastaticbreast cancer that overexpresses HER2., N ENG J MED, 344(11), 2001, pp. 783-792
Immunization of metastatic breast cancer patients with a fully synthetic globe H conjugate: A phase I trial
Authors: Gilewski, T Ragupathi, G Bhuta, S Williams, LJ Musselli, C Zhang, XF Bencsath, KP Panageas, KS Chin, J Hudis, CA Norton, L Houghton, AN Livingston, PO Danishefsky, SJ
Citation: T. Gilewski et al., Immunization of metastatic breast cancer patients with a fully synthetic globe H conjugate: A phase I trial, P NAS US, 98(6), 2001, pp. 3270-3275
Immunization of metastatic breast cancer patients with a fully synthetic Hconjugate: A phase I trial (vol 98, 3270, 2001)
Authors: Gilewski, T Ragupathi, G Bhuta, S Williams, LJ Musselli, C Zhang, XF Bencsath, KP Panageas, KS Chin, J Hudis, CA Norton, L Houghton, AN Livingston, PO Danishefsky, SJ
Citation: T. Gilewski et al., Immunization of metastatic breast cancer patients with a fully synthetic Hconjugate: A phase I trial (vol 98, 3270, 2001), P NAS US, 98(24), 2001, pp. 14186-14186
Social support as a buffer to the psychological impact of stressful life events in women with breast cancer
Authors: Kornblith, AB Herndon, JE Zuckerman, E Viscoli, CM Horwitz, RI Cooper, MR Harris, L Tkaczuk, KH Perry, MC Budman, D Norton, L Holland, JC
Citation: Ab. Kornblith et al., Social support as a buffer to the psychological impact of stressful life events in women with breast cancer, CANCER, 91(2), 2001, pp. 443-454
Association of angiogenesis in lymph node metastases with outcome of breast cancer
Authors: Guidi, AJ Berry, DA Broadwater, G Perloff, M Norton, L Barcos, MP Hayes, DF
Citation: Aj. Guidi et al., Association of angiogenesis in lymph node metastases with outcome of breast cancer, J NAT CANC, 92(6), 2000, pp. 486-492
Detecting gene copy number fluctuations in tumor cells by microarray analysis of genomic representations
Authors: Lucito, R West, J Reiner, A Alexander, J Esposito, D Mishra, B Powers, S Norton, L Wigler, M
Citation: R. Lucito et al., Detecting gene copy number fluctuations in tumor cells by microarray analysis of genomic representations, GENOME RES, 10(11), 2000, pp. 1726-1736
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21
Authors: Gilewski, T Adluri, S Ragupathi, G Zhang, SL Yao, TJ Panageas, K Moynahan, M Houghton, A Norton, L Livingston, PO
Citation: T. Gilewski et al., Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21, CLIN CANC R, 6(5), 2000, pp. 1693-1701
A pilot study of interpersonal psychotherapy by telephone with cancer patients and their partners
Authors: Donnelly, JM Kornblith, AB Fleishman, S Zuckerman, E Raptis, G Hudis, CA Hamilton, N Payne, D Massie, MJ Norton, L Holland, JC
Citation: Jm. Donnelly et al., A pilot study of interpersonal psychotherapy by telephone with cancer patients and their partners, PSYCHO-ONC, 9(1), 2000, pp. 44-56
Long-term results of three randomized trials (58831,58832,58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report
Authors: Vilmer, E Suciu, S Ferster, A Bertrand, Y Cave, H Thyss, A Benoit, Y Dastugue, N Fournier, M Souillet, G Manel, AM Robert, A Nelken, B Millot, F Lutz, P Rialland, X Mechinaud, F Boutard, P Behar, C Chantraine, JM Plouvier, E Laureys, G Brock, P Uyttebroeck, A Margueritte, G Plantaz, D Norton, L Francotte, N Gyselinck, J Waterkeyn, C Solbu, G Philippe, N Otten, J
Citation: E. Vilmer et al., Long-term results of three randomized trials (58831,58832,58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report, LEUKEMIA, 14(12), 2000, pp. 2257-2266
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: Results of the European Organizationfor Research and Treatment of Cancer 58881 Randomized Phase III Trial
Authors: Millot, F Suciu, S Philippe, N Benoit, Y Mazingue, F Uyttebroeck, A Lutz, P Mechinaud, F Robert, A Boutard, P Marguerite, G Ferster, A Plouvier, E Rialland, X Behard, C Plantaz, D Dresse, MF Philippet, P Norton, L Thyss, A Dastugue, N Waterkeyn, C Vilmer, E Otten, J
Citation: F. Millot et al., Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: Results of the European Organizationfor Research and Treatment of Cancer 58881 Randomized Phase III Trial, J CL ONCOL, 19(7), 2000, pp. 1935-1942
Phase I study of a third-generation selective estrogen receptor modulator,LY353381.HCl, in metastatic breast cancer
Authors: Munster, PN Buzdar, A Dhingra, K Enas, N Ni, L Major, M Melemed, A Seidman, A Booser, D Theriault, R Norton, L Hudis, C
Citation: Pn. Munster et al., Phase I study of a third-generation selective estrogen receptor modulator,LY353381.HCl, in metastatic breast cancer, J CL ONCOL, 19(7), 2000, pp. 2002-2009
Phase I studies of anti-epidermal growth factor receptor chimeric antibodyC225 alone and in combination with cisplatin
Authors: Baselga, J Pfister, D Cooper, MR Cohen, R Burtness, B Bos, M D'Andrea, G Seidman, A Norton, L Gunnett, K Falcey, J Anderson, V Waksal, H Mendelsohn, J
Citation: J. Baselga et al., Phase I studies of anti-epidermal growth factor receptor chimeric antibodyC225 alone and in combination with cisplatin, J CL ONCOL, 18(4), 2000, pp. 904-914
HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer
Authors: Berry, DA Muss, HB Thor, AD Dressler, L Liu, ET Broadwater, G Budman, DR Henderson, IC Barcos, M Hayes, D Norton, L
Citation: Da. Berry et al., HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer, J CL ONCOL, 18(20), 2000, pp. 3471-3479
An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel
Authors: Gilewski, T Seidman, A Norton, L Hudis, C
Citation: T. Gilewski et al., An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel, CANC CHEMOT, 46, 2000, pp. S23-S26
Estrogen-receptor status in breast cancer - Reply
Authors: Cummings, SR Grady, D Black, D Eckert, S Krueger, KA Nickelsen, T Glusman, JE Powles, TJ Cauley, JA Norton, L Bjarnason, NH Morrow, M Jordan, VC Lippman, ME Costa, A
Citation: Sr. Cummings et al., Estrogen-receptor status in breast cancer - Reply, J AM MED A, 283(3), 2000, pp. 338-339
Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis (vol 148, pg 779, 2000)
Authors: Hazan, RB Phillips, GR Qiao, RF Norton, L Aaronson, SA
Citation: Rb. Hazan et al., Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis (vol 148, pg 779, 2000), J CELL BIOL, 149(1), 2000, pp. 239-239
Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis
Authors: Hazan, RB Phillips, GR Qiao, RF Norton, L Aaronson, SA
Citation: Rb. Hazan et al., Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis, J CELL BIOL, 148(4), 2000, pp. 779-790
Risultati: 1-25 | 26-40